证券代码：002082 证券简称：万邦德 公告编号：2025-037 万邦德医药控股集团股份有限公司 关于子公司取得发明专利的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 万邦德医药控股集团股份有限公司（以下简称"公司"）子公司万邦德制药 集团有限公司近日收到国家知识产权局的《发明专利证书》，具体情况如下： | 发明名称 | 一种氘代石杉碱甲化合物或其药学上可接受的盐及其 制备方法和应用 | | --- | --- | | 专利类型 | 发明专利 | | 专利号 | 202510032192.2 | | 授权公告日 | 2025.6.10 | | 专利权人 | 万邦德制药集团有限公司 | 本专利创造性的通过氘代修饰技术对石杉碱甲进行结构优化，成功研发出氘 代石杉碱甲新型化合物。石杉碱甲是一种天然生物碱，长期作为胆碱酯酶抑制剂， 用于改善阿尔茨海默病等神经退行疾病患者的认知功能。本次改良，通过将药物 分子中的特定氢原子替换为氘同位素，该化合物较原结构化学稳定性更高、毒性 更小、且延长了代谢半衰期，有望在维持疗效的同时降低给药频率和副作用。 上述专利不会对 ...

Group 1 - The innovation drug sector is experiencing a strong performance due to the recent issuance of a policy aimed at improving public health insurance and supporting innovative drugs [1] - The policy includes the establishment of a commercial health insurance directory for innovative drugs, which is expected to accelerate the development of innovative pharmaceuticals [1] - Several listed pharmaceutical companies have responded to the surge in stock prices, indicating significant market interest and volatility [1] Group 2 - Changshan Pharmaceutical announced a stock price increase of 147.69% from May 6 to June 9, with a cumulative deviation of over 30% in the last two trading days [2] - The company’s Abenanide injection has not yet been launched, and there is uncertainty regarding its approval and market competition [2] - Guoyuan Securities expressed optimism about the future of the innovative drug sector in China, highlighting ongoing research and development progress as a catalyst for investment opportunities [2]

Group 1 - The stock of Wanbangde increased by 6.87% with a turnover rate of 19.86% and a trading volume of 941 million yuan, showing a price fluctuation of 15.30% throughout the day [2] - Institutional investors net bought 9.54 million yuan, while the total net buying from brokerage seats amounted to 11.22 million yuan [2] - The top five brokerage seats accounted for a total trading volume of 132 million yuan, with a net buying of 20.77 million yuan after a buying amount of 76.42 million yuan and a selling amount of 55.66 million yuan [2] Group 2 - The main capital inflow for the stock was 13.09 million yuan, with a significant single net inflow of 14.68 million yuan, while large single capital experienced a net outflow of 1.59 million yuan [2] - Over the past five days, the main capital has seen a net outflow of 8.37 million yuan [2] - Specific brokerage seats showed significant buying activity, with the top buying seat being Lianchu Securities Zhejiang branch, which bought 17.08 million yuan and sold 0.97 million yuan [2]

Group 1 - The A-share innovative drug concept has experienced a volatile rebound, with Changshan Pharmaceutical rising over 16% to reach a historical high [1] - Lianhua Technology increased by more than 9%, indicating positive market sentiment towards innovative drug companies [1] - Other companies such as Anglikang, Sailun Bio, Wanbangde, and Zhongsheng Pharmaceutical also saw gains, reflecting a broader trend in the sector [1]

证券代码：002082 证券简称：万邦德 公告编号：2025-036 针对公司股票异常波动情况，按照相关规定的要求，公司对有关事项进行了 核查，现就核实情况说明如下： 1、前期披露的信息不存在需要更正、补充之处； 2、公司未发现近期公共媒体报道了可能或已经对本公司股票交易价格产生 较大影响的未公开重大信息； 3、公司目前经营情况正常，不存在内外部经营环境发生重大变化的情形； 4、公司、控股股东和实际控制人不存在关于公司应披露而未披露的重大事项 或处于筹划阶段的重大事项； 一、股票交易异常波动的情况介绍 万邦德医药控股集团股份有限公司 万邦德医药控股集团股份有限公司(以下简称"公司"）股票连续 2 个交易日内 （2025 年 5 月 30 日，2025 年 6 月 3 日）收盘价格涨幅偏离值累计达到 21.67%， 根据《深圳证券交易所交易规则》的相关规定，属于股票交易异常波动。 关于股票交易异常波动的公告 二、公司关注并核实的情况 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 五、备查文件 1、关于股票交易异常波动的问询函及回复。 特此公告。 万邦德医药控股 ...

Market Overview - The three major A-share indices rebounded collectively, with the Shanghai Composite Index rising by 0.48%, the Shenzhen Component Index by 0.35%, and the ChiNext Index by 0.73% [1] - The total market turnover reached 763.9 billion yuan, a decrease of 7.7 billion yuan compared to the same period of the previous trading day [1] - Over 3,400 stocks in the market experienced gains [1] Sector Performance - The gold sector led the market, with Western Gold hitting the daily limit [1][9] - The innovative drug sector remained active, with stocks like Wanbangde and Qianhong Pharmaceutical also hitting the daily limit [1] - The new consumption concept saw renewed activity, with stocks like Ruoyuchen and Wancheng Group hitting their historical highs [1][12] Sports Sector Impact - The Jiangsu City Football League ("Su Chao") attracted significant attention, with 15,669 fans attending a match despite rain [3] - The popularity of "Su Chao" translated into the capital market, with Jinling Sports hitting a 20% limit up and 11 stocks in the Jiangsu sector reaching their daily limits [4][6] Gold Market Insights - Gold prices rebounded, with COMEX gold futures surpassing $3,400 per ounce [11] - The gold sector in both A-shares and Hong Kong stocks showed strong performance, with several companies like China Silver Group and Zijin Mining also experiencing gains [9][11] New Consumption Trends - The new consumption sector saw significant growth, with stocks like Ruoyuchen and Wancheng Group achieving historical highs [12] - Recent data indicated that several new consumption stocks have seen their prices more than double, with Ruoyuchen and Wancheng Group increasing over four times [18]

Core Insights - The biovaccine sector saw a rise of 1.01%, ranking 10th among concept sectors, with 33 stocks increasing in value, including Wanbangde, which hit the daily limit, and notable gains from Guanhao Bio, Kexing Pharmaceutical, and Kanghua Bio, which rose by 8.88%, 7.40%, and 6.06% respectively [1][2] - The sector experienced a net inflow of 137 million yuan from main funds, with 31 stocks receiving net inflows, and five stocks exceeding 30 million yuan in net inflows, led by Fosun Pharma with 54.52 million yuan [2][3] Sector Performance - The top-performing sectors included pork (2.39%), chicken farming (1.94%), and innovative drugs (1.56%), while sectors like controllable nuclear fusion (-3.47%) and humanoid robots (-2.90%) faced declines [2] - The biovaccine sector's performance was supported by significant net inflows, with Wanbangde leading with a net inflow rate of 41.21%, followed by Haiwang Bio and Jindike [3] Stock Highlights - Key stocks in the biovaccine sector included: - Fosun Pharma: 5.23% increase, 54.52 million yuan net inflow, 2.82% turnover rate [3] - Taige Pharmaceutical: 3.60% increase, 44.07 million yuan net inflow, 3.92% turnover rate [3] - Wanbangde: 10.02% increase, 42.69 million yuan net inflow, 3.12% turnover rate [3] - Haiwang Bio: 3.57% increase, 34.73 million yuan net inflow, 5.19% turnover rate [3] - Guanhao Bio: 8.88% increase, 21.12 million yuan net inflow, 17.97% turnover rate [3]

一、行情回顾 市场全天震荡调整，创业板指领跌。创新药概念逆势大涨，睿智医药、海南海药、哈三联等多股涨停。猪肉、鸡肉股拉升，巨星农牧、湘佳股份封板。银行 股继续走强，杭州银行、成都银行创历史新高。下跌方面，高位股集体大跌，王子新材等多股跌停。个股跌多涨少，沪深京三市超4100股飘绿，今日成交 1.16万亿。 根据渤海证券统计，本周多款创新药获批上市，包括恒瑞医药的瑞康曲妥珠单抗、磷罗拉匹坦帕洛诺司琼、苹果酸法米替尼，复星医药的枸橼酸伏维西利、 芦沃美替尼，百济神州的泽尼达妥单抗，泽璟制药的盐酸吉卡昔替尼等，同时美国关税政策边际变化带动 CXO 板块快速反弹。 2025年美国临床肿瘤学会（ASCO）即将于当地时间5月30日至6月3日在美国芝加哥召开。 | 股票名称 | | 最新价 = | 涨跌幅 = | 涨停时间 = | 换手率 = | 流通市值 = | | | --- | --- | --- | --- | --- | --- | --- | --- | | 华森制药 | 4天4板 | 20.63 | +10.03% | 09:32:48 | 4.42% | 63.72亿 | 公司旗下5个产品完 美拉唑碳酸氢钠 ...

智通财经5月30日电，创新药概念股盘中持续走强，万邦德、康弘药业、千红制药、华森制药、哈三 联、联化科技、海南海药、华纳药厂、睿智医药等10余股涨停，舒泰神、科兴制药、冠昊生物等涨超 10%。 创新药概念股持续走高 万邦德等10余股涨停 ...

证券代码：002082 证券简称：万邦德 公告编号：2025-034 万邦德医药控股集团股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 万邦德医药控股集团股份有限公司（以下简称"公司"）第九届董事会第十 六次会议通知于 2025 年 5 月 15 日以邮件、电话、微信等方式发出，会议于 2025 年 5 月 20 日在公司行政楼会议室以现场结合通讯方式召开。本次会议由董事长赵 守明先生主持，应出席会议董事 9 人，实际出席董事 9 人，马健先生、周岳江先 生、李杨女士、屠鹏飞先生以通讯方式出席会议并参与表决。公司监事及高级管 理人员列席会议。会议的召集、召开及表决程序符合有关法律法规和《公司章程》 的规定。 二、董事会会议审议情况 会议以记名投票表决的方式审议通过了以下议案： 表决结果：9票同意，0票反对，0票弃权。 经公司董事长提名，提名委员会审核通过，董事会同意聘任柳建朋先生为公 司副总经理及董事会秘书。任期自本次董事会审议通过之日起至本届董事会期满 之日止。 具体内容详见同日披露于巨潮资讯网（www.cninfo.c ...